Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – dienogest

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Antikonceptionella medel Testmiljö

Antikonceptionella medel

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Charlton BM, Mølgaard-Nielsen D, Svanström H, Wohlfahrt J, Pasternak B, Melbye M. Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study. BMJ. 2016;352:h6712.

  2. Wogelius P, Horvath-Puho E, Pedersen L, Nörgaard M, Czeizel AE, Sörensen HT et al. Maternal use of oral contraceptives and risk of hypospadias - a population-based case-control study. Eur J Epidemiol 2006;21:777-81.

  3. Mucci LA, Lagiou P, Hsieh CC, Tamimi R, Hellerstein S, Vatten L et al. A prospective study of pregravid oral contraceptive use in relation to fetal growth. BJOG 2004;111:989-95.

  4. Raman-Wilms L, Tseng AL, Wighardt S et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995;85:141-9.

  5. Källén B, Mastroiacovo P, Lancaster PA et al. Oral contraceptives in the etiology of isolated hypospadias. Contraception 1991;44:173-82.

  6. Källén B. Maternal use of oral contraceptives and Down syndrome. Contraception 1989;39:503-6.

  7. Harlap S, Shiono PH, Ramcharan S. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 1985;30:39-47.

  8. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and birth defects. Am J Epidemiol 1980;112:73-9.

  9. Janerich DT, Glebatis D, Flink E et al. Case-control studies on the effect of sex steroids on women and their offspring. J Chronic Dis 1979;32:83-8.

  10. Bracken MB, Holford TR, White C et al. Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 1978;7:309-17.

  11. Lejeune J, Prieur M. [Oral contraceptives and trisomy 21. A retrospective study of 730 cases (author's transl)]. Ann Genet 1979;22:61-6.

  12. Nora JJ, Nora AH. Editorial: Can the pill cause birth defects? N Engl J Med 1974;291:731-2.

  13. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and congenital limb-reduction defects. N Engl J Med 1974;291:697-700.

  1. Charlton BM, Mølgaard-Nielsen D, Svanström H, Wohlfahrt J, Pasternak B, Melbye M. Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study. BMJ. 2016;352:h6712.
  2. Wogelius P, Horvath-Puho E, Pedersen L, Nörgaard M, Czeizel AE, Sörensen HT et al. Maternal use of oral contraceptives and risk of hypospadias - a population-based case-control study. Eur J Epidemiol 2006;21:777-81.
  3. Mucci LA, Lagiou P, Hsieh CC, Tamimi R, Hellerstein S, Vatten L et al. A prospective study of pregravid oral contraceptive use in relation to fetal growth. BJOG 2004;111:989-95.
  4. Raman-Wilms L, Tseng AL, Wighardt S et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995;85:141-9.
  5. Källén B, Mastroiacovo P, Lancaster PA et al. Oral contraceptives in the etiology of isolated hypospadias. Contraception 1991;44:173-82.
  6. Källén B. Maternal use of oral contraceptives and Down syndrome. Contraception 1989;39:503-6.
  7. Harlap S, Shiono PH, Ramcharan S. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 1985;30:39-47.
  8. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and birth defects. Am J Epidemiol 1980;112:73-9.
  9. Janerich DT, Glebatis D, Flink E et al. Case-control studies on the effect of sex steroids on women and their offspring. J Chronic Dis 1979;32:83-8.
  10. Bracken MB, Holford TR, White C et al. Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 1978;7:309-17.
  11. Lejeune J, Prieur M. [Oral contraceptives and trisomy 21. A retrospective study of 730 cases (author's transl)]. Ann Genet 1979;22:61-6.
  12. Nora JJ, Nora AH. Editorial: Can the pill cause birth defects? N Engl J Med 1974;291:731-2.
  13. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and congenital limb-reduction defects. N Engl J Med 1974;291:697-700.
2 2
2 2

Dienogest Testmiljö

Dienogest

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.

  2. Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988;38:135-44.

  3. WILKINS L. Masculinization of female fetus due to use of orally given progestins. J Am Med Assoc. 1960;172:1028-32.

  4. WILKINS L, JONES HW, HOLMAN GH, STEMPFEL RS. Masculinization of the female fetus associated with administration of oral and intramuscular progestins during gestation: non-adrenal female pseudohermaphrodism. J Clin Endocrinol Metab. 1958;18:559-85.

  5. Brent RL. Nongenital malformations following exposure to pregestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol. 2005;73:906-18.

  6. Thomson Reuters. Micromedex: Reprorisk, TERIS. Progesterone-like Compounds (Progestins), High Dose. Tillgänglig från: www.micromedexsolutions.com. Citerad mars 2018.

  1. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.
  2. Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988;38:135-44.
  3. WILKINS L. Masculinization of female fetus due to use of orally given progestins. J Am Med Assoc. 1960;172:1028-32.
  4. WILKINS L, JONES HW, HOLMAN GH, STEMPFEL RS. Masculinization of the female fetus associated with administration of oral and intramuscular progestins during gestation: non-adrenal female pseudohermaphrodism. J Clin Endocrinol Metab. 1958;18:559-85.
  5. Brent RL. Nongenital malformations following exposure to pregestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol. 2005;73:906-18.
  6. Thomson Reuters. Micromedex: Reprorisk, TERIS. Progesterone-like Compounds (Progestins), High Dose. Tillgänglig från: www.micromedexsolutions.com. Citerad mars 2018.